pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,116 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT824Endpoints628BioPharma Dive239onclive165Fierce Biotech91BioSpace90raps32globenewswire health28
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • STAT+: In private meeting, Trump officials push to onshore generic drugmaking
    Marco Rubio, RFK Jr., and Chris Klomp are urging industry leaders to make more medicines in the U.S.
    STAT · 22d ago↗ source
  • Bryan Johnson’s chronic disease is notoriously difficult to diagnose
    Why longevity entrepreneur Bryan Johnson’s chronic disease is notoriously difficult to diagnose.
    STAT · 22d ago↗ source
  • AstraZeneca, GSK intensify China ties with Sino Biopharm deals
    The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.
    BioPharma Dive · 22d ago↗ source
← prev
page 14 of 45
next →
fda medwatch21
fda press21
fda recalls16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
  • Affordable Care Act insurers want more premium increases as enrollment sags
    For the second year in a row, many Affordable Care Act insurers are proposing double-digit premium increases, driven by rising medical costs as well as federal policy changes.
    STAT · 22d ago↗ source
  • Transplants extended survival for patients whose stage 4 lung cancer hadn’t spread, study says
    Lung cancer patients hadn't been seen as candidates for organ transplant. Now a study finds patients did well.
    STAT · 22d ago↗ source
  • STAT+: Europe will accelerate its review of RevMed’s drug
    Kailera's GLP-1 pill data raises concerns, FDA clears Vera autoimmune therapy, and more biotech news from The Readout
    STAT · 22d ago↗ source
  • STAT+: Prime Medicine claims victory in dispute over gene-editing technology with Beam Therapeutics
    Prime Medicine said it had won an arbitration dispute against Beam Therapeutics, a clash that had pitted two well-backed gene-editing companies against each other.
    STAT · 22d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
    The FDA approved a kidney disease drug from Vera Therapeutics called Trutakna, to treat IgA nephropathy
    STAT · 22d ago↗ source
  • Prime wins gene editing dispute; Saol claims latest post-Makary FDA reversal
    An arbitration panel ruled Prime didn’t breach a deal with Beam by developing a rare disease treatment. Elsewhere, European regulators are using a pancreatic cancer drug to test a new framework for…
    BioPharma Dive · 22d ago↗ source
  • Another big premium hike on the horizon
    FDA's crackdown on online ketamine retailers, unprecedented health care premium hikes, and more health news from Morning Rounds
    STAT · 22d ago↗ source
  • Opinion: STAT+: What’s the right role for AI in dementia care?
    Three tricky questions about using AI in dementia care.
    STAT · 22d ago↗ source
  • Opinion: The AI licensure debate is missing the point of licensure
    “AI will reshape medicine. The physicians who answer for the outcome must lead the way it enters patient care," write Afnan R. Tariq and Ami Bhatt.
    STAT · 22d ago↗ source
  • Are glucose monitors a good thing for 2-year-olds? Experts look at risks, benefits
    The newly approved over-the-counter CGM offers a new approach to tackling childhood obesity but also raises a host of questions.
    STAT · 22d ago↗ source
  • STAT+: Trump administration pursues more durable changes to science policy after setbacks in court
    The White House has proposed sweeping changes to the bedrock regulation undergirding all federal contracts, empowering the executive branch to direct research, terminate grants, and external scient…
    STAT · 22d ago↗ source
  • STAT+: FDA approves Vera Therapeutics kidney disease treatment
    The FDA approved a new medicine from the biotech company Vera Therapeutics for patients with a type of chronic autoimmune kidney disease.
    STAT · 23d ago↗ source
  • Oberland pours up to $400M into MeiraGTx eye gene therapies
    The funding deal is a vote of confidence in the sales potential of multiple prospects in late-stage development — one of which MeiraGTx recently reacquired from J&J.
    BioPharma Dive · 23d ago↗ source
  • Kailera says obesity pill succeeds in late-stage trial in China
    The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.
    BioPharma Dive · 23d ago↗ source
  • STAT+: The crumbling employer-based health insurance system
    Today's D.C. Diagnosis newsletter covers maintaining diversity in drug trials and troubling trends in employer-based health insurance.
    STAT · 23d ago↗ source
  • STAT+: Compass says depression drug has long-lasting benefits
    Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout
    STAT · 23d ago↗ source
  • STAT+: America’s employer health insurance is decaying
    STAT's Bob Herman examines the under-the-radar crisis brewing in employer-based health insurance.
    STAT · 23d ago↗ source
  • STAT+: ‘Secret shopper’ study probes GLP-1 telehealth sites
    In this edition of STAT Health Tech: A 'secret shopper' study of telehealth sites prescribing GLP-1s, news about Epic, Anthropic, and brain implants.
    STAT · 23d ago↗ source
  • Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
    Vertex claimed the two drugs in the deal could eventually bring in more than $5 billion annually. Still, the high price it paid stirred debate among analysts and investors.
    BioPharma Dive · 23d ago↗ source
  • STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more
    Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder
    STAT · 23d ago↗ source
  • Ebola outbreak exposes a fractured outbreak response system
    The costly threat to employer-based health care, Gen Z doctors, and more health news
    STAT · 23d ago↗ source
  • Vera Therapeutics wins FDA nod for closely watched kidney disease drug
    The clearance marks another step forward in treatment for IgA nephropathy and sets up a commercial battle with Otsuka, which brought a similar medication to market last year.
    BioPharma Dive · 23d ago↗ source